Summit Therapeutics price target lowered to $44 from $45 at H.C. Wainwright
The Fly

Summit Therapeutics price target lowered to $44 from $45 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Summit Therapeutics (SMMT) to $44 from $45 and keeps a Buy rating on the shares following the Q3 report.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App